Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By continuing, you are declaring that you are requesting any such information.
If you’re a migraine sufferer, you’ll know how critical it is to find some form of relief from the pain, nausea and dizziness. Simple movements like gazing out the window, checking your phone or playing music become impossible — never mind trying to get through the work day or take care of family.
That’s why a new migraine injection, erenumab (Aimovig), poses promising possibilities for some migraine sufferers.
For some people with debilitating migraines, this medicine may not be available in their country, even though it is approved by regulatory bodies. Potentially for months, or even years. There are ways to import the medicine for personal use, but most people don’t have this knowledge and might not have the logistical understanding of what’s needed. You can get a better understanding of market access delays on our home page. We provide all the knowledge needed and should you wish to order, our team of qualified pharmacists and professionals will guide you through the process.
What is erenumab (Aimovig)?
Erenumab (Aimovig) is a migraine injection, normally taken once per month. It’s unique because it is the first and only CGRP receptor blocker for migraine. It works by aiming to stop the onset of migraines before they arrive, rather than only working to treat the symptoms and pain of migraines after they arrive. Results also show that erenumab may be helpful in reducing the severity of migraines when they do happen.
To take the medicine, it's expected that patients will inject themselves. The injection process is made as simple as possible: the medicine arrives in an applicator package, with a very thin needle.
In this video, an American doctor shows how to self-administer this medicine.
The good news is, the effectiveness of erenumab does not seem to be affected by age, gender, or race – based on the clinical trial results.
The trials also showed that erenumab works similarly for those who have episodic (less than 15 migraines per month) migraines and those who have chronic migraines (more than 15 migraines per month), which suggests it may be a useful treatment for all kinds of people, who have all kinds of migraines.
In the clinical trials for Aimovig, the most common side effects are a reaction where the medicine is injected, and constipation. Erenumab may reduce the severity and number of migraines experienced in a month, and therefore may have significant benefits for those who’ve struggled with the debilitating condition for years.
Have you used erenumab (Aimovig)? Share your experience.
If you have already used erenumab please let us know, because we would like to share real experiences of using this novel medicine with other migraine sufferers. Email us at: firstname.lastname@example.org
Are you a migraine sufferer?
If you suffer from migraines and are interested in sourcing treatment options not available in your country, head to our home page to find out more about how we can help you.